PER® Chemotherapy Foundation Symposium (CFS) | Conference

BRAF/MEK Combination Highly Effective in Melanoma

November 6th 2015

Adding the MEK inhibitor trametinib to the BRAF inhibitor dabrafenib significantly improves long-term outcomes while lowering certain adverse events associated with either agent alone for patients with BRAF-mutated metastatic melanoma.

Dr. Weber on Dabrafenib/Trametinib Approval for Melanoma

November 6th 2015

Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program and Head of Experimental Therapeutics, NYU Langone Medical Center, discusses the significance of the FDA approval of the combination of dabrafenib and trametinib for patients with unresectable or metastatic melanoma who harbor a BRAF V600E or V600K mutation.

Dr. Blackwell on Emerging Therapies in TNBC

November 6th 2015

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses emerging therapies for patients with triple-negative breast cancer.

Dr. Philip on Olaratumab for Soft Tissue Sarcoma

November 6th 2015

Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses approved and emerging agents for soft tissue sarcomas.

Targeted Therapies Improve Outcomes in Advanced Thyroid Cancer

November 5th 2015

The kinase inhibitors sorafenib and lenvatinib have significantly altered the treatment paradigm for patients with advanced radioactive iodine-refractory differentiated thyroid cancer in both older and younger populations.

Dr. Borgen on Surgical Versus Medical Treatment of Breast Cancer

November 5th 2015

Patrick I. Borgen, MD, chair, Department of Surgery, head, Brooklyn Cancer Center, Maimonides Medical Center, compares the efficacy of surgical versus medical treatment of patients with breast cancer.

In Pursuit of Less Toxic Treatments for HPV+ Oropharyngeal Cancers

November 5th 2015

While the prognosis remains good for individuals with HPV-positive oropharyngeal cancers, the incidence of these cancers continues to rise, and researchers are currently seeking less intense treatment options that are equally effective but not as toxic for patients.

Is Neoadjuvant Chemo Justified in Ovarian Cancer?

November 5th 2015

The use of neoadjuvant chemotherapy in advanced ovarian cancer continues to increase, even though the practice has not been shown to improve survival versus primary cytoreduction.

Dr. Muggia on Current Status of Intraperitoneal Therapy for Gynecologic Cancers

November 5th 2015

Franco Muggia, MD, professor of Medicine, NYU Langone Medical Center, discusses the current status of intraperitoneal therapy for patients with gynecologic malignancies.

Immunotherapy Not Ready for Prime Time in Ovarian Cancer

November 5th 2015

Early promising responses seen with immune checkpoint inhibitors for patients with ovarian cancer still need to be validated in larger randomized trials before a conclusion is made regarding their true efficacy.

Dr. Wu on Efficacy of Approved Agents in Colorectal Cancer

November 4th 2015

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the efficacy of regorafenib and TAS-102 for the treatment of patients with colorectal cancer.

Novel Antibodies Arrive in ALL

November 4th 2015

Monoclonal antibodies are poised to revolutionize the treatment of adult patients with relapsed acute lymphoblastic leukemia, specifically blinatumomab and inotuzumab ozogamicin.

Combinations Key to Optimizing Novel Antibodies in Myeloma

November 4th 2015

Optimizing outcomes with novel antibodies in multiple myeloma will involve combination regimens with established agents.

Individualizing Care for Patients With Polycythemia Vera

November 4th 2015

The landscape for the diagnosis and treatment of polycythemia vera (PV) is changing, and that's good news for patients and practitioners who can look to improvements ahead.

Dr. Landgren Discusses MRD Detection for Multiple Myeloma

November 4th 2015

C. Ola Landgren, MD, PhD, hematologic oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses minimal residual disease detection for progression-free survival and overall survival for patients with multiple myeloma.

B-cell Pathway Inhibitors Show Clear Benefit in CLL

November 4th 2015

B-cell pathway inhibitors have shown impressive survival benefits for patients with chronic lymphocytic leukemia, but require careful monitoring and possible suspension to control adverse events.

Dr. Venook Discusses the Approval of Ramucirumab Plus Paclitaxel

November 7th 2014

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the approval of ramucirumab plus paclitaxel for gastric cancer

Immunotherapeutic Strategies in Head and Neck Cancer

November 7th 2014

Both HPV-positive and -negative head and neck cancers are "outstanding candidates for immunotherapeutic strategies," said Andrew G. Sikora, MD, PhD, Baylor College of Medicine, at the 2014 Chemotherapy Foundation Symposium.

New Research Focuses on Personalized Treatments in Ovarian Cancer

November 6th 2014

Translating current and emerging knowledge of the molecular drivers of ovarian cancer is yielding promising new insights into potential clinical targets, moving treatment away from historical paradigms in favor of more personalized therapeutic approaches.

Safra Provides an Overview of PARP Inhibitors in Ovarian Cancer

November 6th 2014

PARP inhibitors represent an important class of emerging therapies for the treatment of patients with ovarian cancer and possibly other malignancies, but many scientific questions about the underlying molecular mechanisms that these agents target must be answered before they can be fully employed in clinical practice.